Phase 1/2, Multicenter, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer
Latest Information Update: 17 Aug 2024
At a glance
- Drugs Patritumab Deruxtecan (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 13 Dec 2023 Status changed from active, no longer recruiting to completed.
- 16 Oct 2023 According to a Daiichi Sankyo Company media release, data from this will be presented at the European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023.
- 06 Oct 2023 Results of an analysis reporting efficacy and safety results across clinical subtypes: hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer and HER2-positive breast cancer published in the Journal of Clinical Oncology